Teva UK "wholeheartedly" welcomes generic substitution consultation
Posted on 07/01/2010 in Pharmacy Supplier News
Teva UK "wholeheartedly" welcomes the Department of Health's preferred proposal on generic substitution, its commercial operations officer has said.
Richard Daniell stated that generic therapies are able to provide the same standards of safety, efficacy and quality as the originator brands at an average of 20 per cent of the cost.
The department's favoured proposal would allow dispensers to transfer a prescription from a named-branded drug to a cheaper generic equivalent for a select list of treatments. An opt-out endorsement would also exist.
Mr Daniell added: "This is the ideal opportunity to save millions - or even billions - more whilst providing proven and effective healthcare for millions of patients across the UK."
A three-month consultation period will now take place, allowing interested parties to offer their input and opinions on the proposals.
Teva UK made its assertions after it announced the launch of its first biosimilar - TevaGrastim - in November 2009.
